GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » PE Ratio (TTM)

Grifols (MEX:GRF N) PE Ratio (TTM) : N/A (As of Jul. 08, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Grifols PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2025-07-08), Grifols's share price is MXN0.00. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00. Therefore, Grifols's PE Ratio (TTM) for today is N/A.


The historical rank and industry rank for Grifols's PE Ratio (TTM) or its related term are showing as below:

MEX:GRF N' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 15.84   Med: 29.51   Max: 140.11
Current: 53.58


During the past 13 years, the highest PE Ratio (TTM) of Grifols was 140.11. The lowest was 15.84. And the median was 29.51.


MEX:GRF N's PE Ratio (TTM) is ranked worse than
80.26% of 618 companies
in the Drug Manufacturers industry
Industry Median: 23.88 vs MEX:GRF N: 53.58

Grifols's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was MXN2.21. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00.

As of today (2025-07-08), Grifols's share price is MXN0.00. Grifols's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00. Therefore, Grifols's PE Ratio without NRI for today is N/A.

During the past 13 years, Grifols's highest PE Ratio without NRI was 140.11. The lowest was 15.81. And the median was 29.40.

Grifols's EPS without NRI for the three months ended in Dec. 2024 was MXN2.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00.

During the past 12 months, Grifols's average EPS without NRI Growth Rate was 266.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was -2.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -31.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -16.80% per year.

During the past 13 years, Grifols's highest 3-Year average EPS without NRI Growth Rate was 86.80% per year. The lowest was -54.60% per year. And the median was 5.60% per year.

Grifols's EPS (Basic) for the three months ended in Dec. 2024 was MXN2.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was MXN4.27.


Grifols PE Ratio (TTM) Historical Data

The historical data trend for Grifols's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols PE Ratio (TTM) Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.53 60.27 39.89 257.58 39.77

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.98 257.58 41.15 57.12 39.77

Competitive Comparison of Grifols's PE Ratio (TTM)

For the Drug Manufacturers - General subindustry, Grifols's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's PE Ratio (TTM) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Grifols's PE Ratio (TTM) falls into.


;
;

Grifols PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Grifols's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Grifols's Share Price of today is MXN0.00.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Grifols  (MEX:GRF N) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Grifols PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Grifols's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines